Market Overview

UPDATE: BTIG Research Initiates Coverage On Histogenics On NeoCart Potential

Share:

In a report published Friday, BTIG Research analyst Sean Lavin initiated coverage on Histogenics Corp. (NASDAQ: HSGX) with a Buy rating and $13.00 price target.

In the report, BTIG Research noted, “Histogenics' NeoCart is likely to be the first regenerative tissue implant available in the U.S. with both cells and a scaffold to treat articular cartilage damage. Many companies have attempted to grow cartilage but have failed for a variety of reasons. It seems that, based on compelling Phase II data, Histogenics has developed proprietary tissue engineering techniques that make it likely that the Phase III data will also look compelling. We believe Histogenics will have a significant first-mover advantage and that other treatment options all have inadequate outcomes, the market is ~$10B in the U.S. and growing, the product should save the healthcare system money and the upside in owning shares is greater than the downside, though it is a binary around Phase III data, FDA approval and reimbursement.”

Histogenics closed on Thursday at $8.43.

Latest Ratings for HSGX

DateFirmActionFromTo
Dec 2018DowngradesBuyNeutral
Sep 2018DowngradesBuyNeutral
Dec 2016Initiates Coverage OnBuy

View More Analyst Ratings for HSGX
View the Latest Analyst Ratings

Posted-In: BTIG Research Sean LavinAnalyst Color Initiation Analyst Ratings

 

Related Articles (HSGX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ARCHBMO CapitalMaintains110.0
REZIBank of AmericaDowngrades
GOLFMorgan StanleyDowngrades27.0
VBTXRaymond JamesMaintains28.0
IRBTPiper JaffrayReiterates51.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Kyle Bass On CNBC: General Motors Could Double Its Dividend

Morning Market Losers